These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 38842750)

  • 1. Safety evaluation of ceftazidime/avibactam based on FAERS database.
    Zhang X; Jiang Y; Guo Y; Zhou W; Qiao W; Zhu H; Qi Z
    Infection; 2024 Dec; 52(6):2195-2205. PubMed ID: 38842750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suspected adverse drug reactions of rivaroxaban reported in the United States food and drug administration adverse event reporting system database: a pharmacovigilance study.
    Wu J; Wu J; Tang B; Wang X; Wei F; Zhang Y; Li L; Li H; Wang B; Wu W; Hong X
    Front Pharmacol; 2024; 15():1399172. PubMed ID: 39309013
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A disproportionality analysis of low molecular weight heparin in the overall population and in pregnancy women using the FDA adverse event reporting system (FAERS) database.
    Xu H; Xu N; Wang Y; Zou H; Wu S
    Front Pharmacol; 2024; 15():1442002. PubMed ID: 39188956
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unveiling potential adverse events associated with escitalopram oxalate: A real-world analysis based FDA adverse event reporting system database.
    Jiang Y; Cheng Y; Du Z; Shen Y; Zhou Q; Ji Y; Zhu H
    J Psychopharmacol; 2024 Jun; 38(6):567-578. PubMed ID: 38678377
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Signal mining and analysis for central nervous system adverse events due to taking oxycodone based on FAERS database.
    Wu X; Zhang L; Huang H; Huang L; Lu X; Wang Z; Xiao J
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2023 Mar; 48(3):422-434. PubMed ID: 37164926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment of adverse events of the novel cardiovascular drug vericiguat: a real-world pharmacovigilance study based on FAERS.
    Rao J; Chen X; Liu Y; Wang X; Cheng P; Wang Z
    Expert Opin Drug Saf; 2024 Oct; 23(10):1317-1325. PubMed ID: 39021273
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib safety evaluation: Real-world analysis of adverse events from the FAERS database.
    Ning L; Tian Y; Chen D; Han J; Xie G; Sun J
    Heliyon; 2024 Sep; 10(18):e37348. PubMed ID: 39309940
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Analysis of post-market adverse events of istradefylline: a real-world study base on FAERS database.
    Jiang Y; Lu R; Zhou Q; Shen Y; Zhu H
    Sci Rep; 2024 Apr; 14(1):7659. PubMed ID: 38561511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mining and evaluation of adverse event signals for capmatinib based on the FAERS database.
    Chen X; Jiang Y; Zhu H; Tian M
    Front Pharmacol; 2024; 15():1417661. PubMed ID: 39380910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Real-World Pharmacovigilance Study of the FDA Adverse Event Reporting System Events for Trametinib.
    Zhang X; Li R; Li Y; He L; Hou E
    Cureus; 2024 Aug; 16(8):e67925. PubMed ID: 39328691
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacovigilance of esketamine nasal spray: an analysis of the FDA adverse event reporting system database.
    Liu R; Liu C; Feng D; Guo T; Wang Y
    Front Pharmacol; 2024; 15():1414703. PubMed ID: 38948465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety evaluation of bempedoic acid: A pharmacovigilance analysis using FDA adverse event reporting system data.
    Li B; Zhang J; Huang A; Chen Y; Wei Q
    Int J Cardiol; 2024 Oct; 412():132305. PubMed ID: 38944350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety assessment of Brexpiprazole: Real-world adverse event analysis from the FAERS database.
    Jiang Y; Zhou L; Shen Y; Zhou Q; Ji Y; Zhu H
    J Affect Disord; 2024 Feb; 346():223-229. PubMed ID: 37956832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A disproportionality analysis of FDA adverse event reporting system (FAERS) events for ticagrelor.
    Pan Y; Wang Y; Zheng Y; Chen J; Li J
    Front Pharmacol; 2024; 15():1251961. PubMed ID: 38655177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Post-marketing safety surveillance of sacituzumab govitecan: an observational, pharmacovigilance study leveraging FAERS database.
    Liu W; Du Q; Guo Z; Ye X; Liu J
    Front Pharmacol; 2023; 14():1283247. PubMed ID: 38027003
    [No Abstract]   [Full Text] [Related]  

  • 16. A Real‑World Pharmacovigilance Study of FDA Adverse Event Reporting System (FAERS) for Mavacamten.
    Yukselen Z; Raju AKV; Kumar PA; Ujjawal A; Dasari M; Parajuli S; Nakhla M; Bansal K; Ganatra S; Dani SS
    Am J Cardiovasc Drugs; 2024 Nov; 24(6):791-799. PubMed ID: 39164512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety assessment of basiliximab using real-world adverse event data from the FDA Adverse Event Reporting System Database: A retrospective observational study.
    Chen S; Ma X; Zhang J
    Medicine (Baltimore); 2024 Sep; 103(36):e39537. PubMed ID: 39252278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Disproportionality analysis of quinolone safety in children using data from the FDA adverse event reporting system (FAERS).
    Kong W; Mao W; Zhang L; Wu Y
    Front Pediatr; 2022; 10():1069504. PubMed ID: 36714649
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring adverse events of Vilazodone: evidence from the FAERS database.
    Jiang Y; Qu Y; Du Z; Ou M; Shen Y; Zhou Q; Tian L; Zhu H
    BMC Psychiatry; 2024 May; 24(1):371. PubMed ID: 38755677
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A real-world disproportionality analysis of ospemifene: data mining of the public version of FDA adverse event reporting system.
    Wen H; Lu C; Zhang M; Qi X
    Expert Opin Drug Saf; 2023; 22(11):1133-1142. PubMed ID: 37578751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.